These trials showed clinically substantial pharmacokinetic interactions [seven] characterized by a decrease in the clearance of the anticancer drug and hence amplified exposure. The interpretation of subsequent section II and III medical trials was difficult as it was not possible to administer the identical dose of chemotherapy in the presence https://aesopq888cwp3.wikicarrier.com/user